Showing 1541-1550 of 2050 results for "".
- Suspected Control Group Participant in AstraZeneca COVID-19 Vaccine Study Dies; Trial Continueshttps://modernod.com/news/suspected-control-group-participant-in-astrazeneca-covid-19-vaccine-study-dies-trial-continues/2478449/Brazilian health authority Anvisa said that a participant in a clinical trial there of AstraZeneca’s experimental COVID-19 vaccine AZD1222 died earlier this week, but added that the study would nevertheless go on. AstraZeneca stated it cannot comment on individual cases because of confident
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/Alcon celebrates World Sight Day through its corporate giving and company-led initiatives focused on improving access to quality eye care. In the spirit of this year’s theme, “Hope in Sight,” Alcon associates will help spark donations to global nonprofit organizations that advance eye health. The
- Trump Administration Strips CDC of Control of Coronavirus Datahttps://modernod.com/news/trump-administration-strips-cdc-of-control-of-coronavirus-data/2478021/
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Mobius Therapeutics Continues Production and Distribution of Mitosolhttps://modernod.com/news/mobius-therapeutics-continues-production-and-distribution-of-mitosol/2477540/Mobius Therapeutics, the maker of Mitosol (mitomycin for solution) 0.2 mg/vial kit for ophthalmic use, has maintained production and inventory of Mitosol, recognizing the nonelective nature of the patient population affected by its intended use. Mitosol is the only FDA approved
- FDA Calls for Withdrawal of Ranitidine Products as Review Finds Contaminant Could Pose Riskhttps://modernod.com/news/fda-calls-for-withdrawal-of-ranitidine-products-as-review-finds-contaminant-could-pose-risk/2477519/The FDA requested that manufacturers immediately pull all prescription and over-the-counter (OTC) ranitidine drugs from the market, saying new evidence indicates users could be exposed to “unacceptable levels” of the probable carcinogen N-nitrosodimethylamine (NDMA) over time under ce
- Controversies in Ophthalmology: Europe (COPHy) Postpones COPHy EU Meetinghttps://modernod.com/news/controversies-in-ophthalmology-europe-cophy-postpones-cophy-eu-meeting/2477396/
- Optimal Atropine Concentration for Two Year Myopia Control Affirmedhttps://modernod.com/news/optimal-atropine-concentration-for-two-year-myopia-control-affirmed/2477255/Atropine 0.05% remains the optimal concentration for slowing myopia progression among Chinese children, the LAMP study extension shows, according to a Reuters report. In a 2011 study, atropine 0.01% – but not 0.1% or 0.5% 
- Johnson & Johnson Vision Ceases Customer-Facing Operations for Sightbox Online Contact Lens Subscription Servicehttps://modernod.com/news/johnson-johnson-vision-ceases-customer-facing-operations-for-sightbox-online-contact-lens-subscription-service/2477054/
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held